Do ACE-inhibitors suppress tumour necrosis factor-α production in advanced chronic renal failure?

Journal of Internal Medicine

Volumn 246, Issue 5, 1999, Pages 503-507

  Stenvinkel, Peter ^a   Andersson, P ^a   Wang, T ^a   Lindholm, B ^a   Bergstrom J ^a   Palmblad, J ^a   Heimburger O ^a   Cederholm, T ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACE inhibitors; Chronic renal failure; Malnutrition; TNF

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PATIENT SELECTION; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUTRITION DISORDERS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032732242     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00560.x     Document Type: Article

References (22)

1. 1 Bergström J, Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int 1993; 34: S39-S50.
2. 2 Shaldon S, Koch KM, Dinarello CA. Interleukin-1 activation and acute phase response during hemodialysis. Contrib Nephrol 1988; 61: 18-26.
3. 3 Cederholm T, Wretlind B, Hellström K et al. Enhanced generation of interleukins 1β and 6 may contribute to the cachexia of chronic disease. Am J Clin Nutr 1997; 65: 876-82.
4. 4 Bergström J, Lindholm B. Malnutrition, cardiac disease and mortality: an integrated point of view. Am J Kidney Dis 1998; 32: 1-10.
5. 5 Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1β, TNF-α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-6.
6. 6 Aguilera A, Codoceo R, Selgas R et al. Anorexigen (TNF-α, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD): their relationship with nutritional parameters. Nephrol Dial Transpl 1998; 13: 1476-83.
7. 7 McKenna RM, MacDonald C, Bernstein KN, Rush DN. increased production of tumor necrosis factor activity by hemodialysis but not peritoneal dialysis patients. Nephron 1994; 67: 190-6.
8. 8 Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumor necrosis factor-α in severe congestive cardiac failure. Br Heart J 1993; 70: 141-3.
9. 9 Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
10. 10 di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150: 1453-5.
11. 11 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
12. 12 Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converling-Enzyme Inhibition and Progressive Renal Discase Study Group. Ann Intern Med 1997; 127: 337-45.
13. 13 Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled study. Ann Int Med 1998; 128: 982-8.
14. 14 The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
15. 15 CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the north Scandinavian enalapril survival study. N Engl J Med 1987; 316: 1429-35.
16. 16 Schindler R, Dinarello CA, Koch KM. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 1995; 7: 526-33.
17. 17 Anderson P, Cederholm T, Palmblad J. Captopril reduces TNP-α induced IL-1β synthesis in human peripheral blood monocytes (Abstract). J Invest Med 1998; 46: 196A.
18. 18 Fukuzawa M, Satoh J, Sagara M et al. Angiotensin-converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997; 36: 49-55.
19. 19 Peeters AC, Netea MG, Kullberg BJ, Thien T, van der Meer JW. The effect of renin-angiotensin inhibitors on pro-and anti-inflammatory cytokine production. Immunology 1998; 94: 376-9.
20. 20 Stenvinkel P, Heimbürger O, Tuck C, Berglund L. Apo (a) isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998; 53: 1336-42.
21. 21 Baker JP, Detsky AS, Wesson DE et al. Nutritional assessment: a comparison of clinical judgment and objective measurements. N Engl J Med 1982; 306: 969-72.
22. 22 Plata-Salamán CR. Cytokines and anorexia: a brief overview. Seminars Oncol 1998; 25: 64-72.